CervoMed Inc. (CRVO) intrinsic value & 10-year financials
CervoMed Inc. (CRVO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 25.1% a year to $4.0M, with an average return on invested capital of -550.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.24
- Market cap
- $7.3M
- Revenue (FY2025)
- $4.0M
- Revenue growth (10-yr CAGR)
- -25.1%
- ROIC (10-yr avg)
- -550.7%
- Free cash flow (FY2025)
- —
CRVO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $4.0M | -$27.0M | — | — | -706.2% | — |
| FY2024 | $9.7M | -$16.3M | — | — | -187.2% | — |
| FY2023 | $7.1M | -$2.2M | — | — | -109.3% | — |
| FY2022 | $0 | -$15.6M | $2,038,891.00 | — | — | — |
| FY2021 | — | -$24.1M | $97,626,748.00 | — | — | -1232.4% |
| FY2020 | — | -$14.2M | $53,831,973.00 | — | — | -229.9% |
| FY2019 | — | -$11.8M | $6,706,509.00 | — | — | -189.6% |
| FY2018 | — | -$18.4M | -$8.21 | — | — | — |
| FY2017 | — | -$1.4M | -$1.94 | -$12.8M | — | — |
| FY2016 | — | -$18.0M | -$1.76 | -$10.8M | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CervoMed Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
CervoMed Inc. has historically struggled to out-earn its cost of capital, averaging just -5.5% ROIC.
CervoMed Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CervoMed Inc. is modeled at -32.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-100300644.16 per share.